Recruitment Screener - Web

Data to Support Drug Product Communications

Recruitment Screener - Web

OMB: 0910-0695

Document [docx]
Download: docx | pdf

Shape1

OMB# 0910-0695
Exp. 3/31/2024



Studies to Enhance FDA Communications Addressing Biosimilar Drug Products:

Patient Interview Screener


[Display at bottom of Introduction screen]

According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0910-0695 and the expiration date is 3/31/2024. The time required to complete this information collection is estimated to average 5 minutes per response to answer the questions to determine eligibility.


Biosimilars Patient Study

Phase 2 Web Screener


Introduction

Thank you for your interest in this study sponsored by the U.S. Food and Drug Administration. Please answer the following questions to see if you are eligible to participate in an online interview about health-related materials for a specific type of medicine.


The interview will be led by a researcher through an online video platform. If you’re eligible for the interview , you can participate from home using a computer and web camera. The discussion will last about 90 minutes. You will be emailed about your $75 honorarium within one business day after the interview concludes and have the option to choose between a physical or electronic gift card.


To determine your eligibility for this study, we need to ask you a few questions. These questions should take no more than 5 minutes.


  1. What is your age?

Age 18 or older

CONTINUE

Under 18

TERMINATE

___ years [Allow 1–99]

  1. Have you ever worked…? [Accept multiple responses.]

    For a drug or pharmaceutical company

    TERMINATE

    For a market research or marketing company, including RTI International or L&E Research

    TERMINATE

    For the U.S. federal government (not including as a member of the military)

    TERMINATE

    As a medical professional (such as a physician, nurse, or pharmacist)

    TERMINATE

    None of the above

    CONTINUE

  2. When was the last time you participated in an interview or a focus group for a research study?

    Within the last 6 months

    TERMINATE

    More than 6 months ago

    CONTINUE

    Never

    CONTINUE

    Don’t know

    TERMINATE

  3. To participate in this study, you will need a desktop computer, laptop computer, or a tablet (not just a smartphone). Which type of device are you most likely to use if you participate in the study?

    Desktop computer

    CONTINUE

    Laptop computer

    CONTINUE

    Tablet (e.g., iPad)

    CONTINUE

    I don’t have any of the devices listed above

    TERMINATE

  4. To participate in this study, you will also need a webcam (attached or built into the device) and high-speed Internet access. Can you meet these requirements?

    Yes

    CONTINUE

    No

    TERMINATE

  5. Do you have any vision, hearing, or speaking issues that would prevent you from reviewing English-language written materials and videos during the interview?

    Yes

    TERMINATE

    No

    CONTINUE

  6. Are you okay with being audio and video recorded during the interview?

    Yes

    CONTINUE

    No

    TERMINATE

  7. Has a healthcare professional ever diagnosed you with any of the following medical conditions? [Accept multiple responses.]

Ankylosing spondylitis / Spondyloarthritis


Ask Q9, then CONTINUE to Q14

Psoriatic arthritis


Ask Q9, then CONTINUE to Q14

Rheumatoid arthritis


Ask Q9, then CONTINUE to Q14

Cancer


Ask Q9, then CONTINUE to Q10

Crohn’s disease


Ask Q9, then CONTINUE to Q14

Ulcerative colitis


Ask Q9, then CONTINUE to Q14

Eczema / Atopic dermatitis


Ask Q9, then CONTINUE to Q14

Psoriasis


Ask Q9, then CONTINUE to Q14

Type 1 diabetes


Ask Q9, then CONTINUE to Q12

Type 2 diabetes


Ask Q9, then CONTINUE to Q12

None of the above

SKIP to Q14


  1. How long ago were you diagnosed with [condition]? [Ask for each condition selected by respondent] [Allow 1–99 years and 0-12 months]

    ___ years

    ___ months (if less than 1 year)


  2. Which type(s) of cancer were you diagnosed with? [Accept multiple responses]

    Breast

    CONTINUE

    Colorectal

    CONTINUE

    Kidney

    CONTINUE

    Leukemia

    CONTINUE

    Lung

    CONTINUE

    Lymphoma

    CONTINUE

    Myeloma

    CONTINUE

    Skin

    CONTINUE

    Other (please specify)

    CONTINUE

  3. Have you ever been diagnosed by a healthcare professional with neutropenia, a blood-related side effect of chemotherapy?

    Yes

    CONTINUE to Q14

    No

    CONTINUE to Q14

  4. How long have you been using insulin to treat your diabetes?

    More than one month

    CONTINUE

    Less than one month


    SKIP to Q14

    Not currently taking insulin

    SKIP to Q14

  5. Do you take insulin at least once per day?

    Yes

    CONTINUE to Q14

    No

    CONTINUE to Q14

  6. Are you the parent or guardian of a child who has been diagnosed with diabetes by a healthcare professional? If so, which type of diabetes?

    Yes, type 1 diabetes

    CONTINUE

    Yes, type 2 diabetes

    CONTINUE

    No

    SEE Q19 INSTRUCTIONS

  7. What is this child’s age?

___ years [Allow 1–99]


Age 18 or older


TERMINATE IF Q8=None of the above

Under 18


CONTINUE

  1. How involved are you in managing your child’s diabetes (e.g., scheduling doctor’s appointments, making medication decisions, administering insulin)?

    Extremely involved

    CONTINUE

    Frequently involved

    CONTINUE

    Somewhat involved

    SEE Q19 INSTRUCTIONS

    Not at all involved

    SEE Q19 INSTRUCTIONS

  2. How long has your child been using insulin to treat his or her diabetes?

    More than one month

    CONTINUE

    Less than one month

    SEE Q19 INSTRUCTIONS

    Not currently taking insulin

    SEE Q19 INSTRUCTIONS

  3. Does your child take insulin at least once per day?

Yes

SEE SKIP PATTERN BELOW

No

SEE SKIP PATTERN BELOW

[Skip pattern:

    • If individual’s responses have checked one or more of the yellow boxes, proceed to Q19.

    • If individual’s responses have checked only the green boxes, skip to Q21

    • If no yellow or green boxes selected, terminate and display closing script.]

  1. These next questions ask about medicines that you take for your health condition(s). Have you ever taken one or more of the following medicines to treat [display condition(s) based on responses to Q8, Q10, and Q11]?

[Display list of medications only for applicable medical conditions in Q8, Q10, and Q11.]

[Allow multiple responses. If one or more medications selected, continue to Q20. If no medications selected, terminate.]

[RECRUIT AT LEAST 20% TAKING AT LEAST ONE BIOSIMILAR]

List of Medicines for Q19

Condition

Medicines

Brand Name [pronunciation] [generic Name]

Ankylosing Spondylitis/ Spondyloarthritis

  • Avsola [av-SO-luh] [infliximab-axxq] (biosimilar)

  • Cimzia [SIM-zi-ah] [certolizumab]

  • Cosentyx [koh-SEN-tix] [secukinumab]

  • Enbrel [EN-brel] [etanercept]

  • Erelzi [Ee-REL-zee] [etenercept-szzs] (biosimilar)

  • Eticovo [Et-uh-co-vo] [etanercept-ykro] (biosimilar)

  • Humira [hu-MEER-ah] [adalimumab]

  • Inflectra [In-flec-tra] [infliximab-dyyb] (biosimilar)

  • Ixifi [ix-IF-ee] [infliximab-qbtx] (biosimilar)

  • Remicade [REM-i-cade] [infliximab]

  • Renflexis [ren-FLEX-is] [infliximab-abda] (biosimilar)

  • Simponi [SIM-poh-nee] [golimumab]

  • Taltz [Taltz] [xekixumab]

Psoriatic Arthritis

  • Avsola [av-SO-luh] [infliximab-axxq] (biosimilar)

  • Cimzia [SIM-zi-ah] [certolizumab]

  • Cosentyx [koh-SEN-tix] [secukinumab]

  • Enbrel [EN-brel] [etanercept]

  • Erelzi [Ee-REL-zee] [etenercept-szzs] (biosimilar)

  • Eticovo [Et-uh-co-vo] [etanercept-ykro] (biosimilar)

  • Humira [hu-MEER-ah] [adalimumab]

  • Inflectra [In-flec-tra] [infliximab-dyyb] (biosimilar)

  • Ixifi [ix-IF-ee] [infliximab-qbtx] (biosimilar)

  • Orencia [oh-REN-see-ah] [abatacept]

  • Otezla [oh-TEZ-la] [apremilast]

  • Remicade [REM-i-cade] [infliximab]

  • Renflexis [ren-FLEX-is] [infliximab-abda] (biosimilar)

  • Simponi [SIM-poh-nee] [golimumab]

  • Simponi Aria [golimumab], IV Infusion

  • Stelara [stuh-LAIR-ah] [ustekinumab]

  • Taltz [Taltz] [xekixumab]

  • Xeljanz [ZEL-janz] [tofacitinib]




Rheumatoid Arthritis

  • Actemra [ac-tEm-ra] [tocilizumab]

  • Avsola [av-SO-luh] [infliximab-axxq] (biosimilar)

  • Cimzia [SIM-zi-ah] [certolizumab]

  • Cosentyx [koh-SEN-tix] [secukinumab]

  • Enbrel [EN-brel] [etanercept]

  • Erelzi [Ee-REL-zee] [etenercept-szzs] (biosimilar)

  • Eticovo [Et-uh-co-vo] [etanercept-ykro] (biosimilar)

  • Humira [hu-MEER-ah] [adalimumab]

  • Inflectra [In-flec-tra] [infliximab-dyyb] (biosimilar)

  • Ixifi [ix-IF-ee] [infliximab-qbtx] (biosimilar)

  • Kevzara [kev-ZAR-a] [sarilumab]

  • Kineret [KIN-er-et] [anakinra]

  • Orencia [oh-REN-see-ah] [abatacept]

  • Remicade [REM-i-cade] [infliximab]

  • Renflexis [ren-FLEX-is] [infliximab-abda] (biosimilar)

  • Rinvoq [RIN-voke] [upadacitinib]

  • Rituxan [rih-TUK-sun] [rituximab]

  • Stelara [stuh-LAIR-ah] [ustekinumab]

  • Simponi [SIM-poh-nee] [golimumab]

  • Xeljanz [ZEL-janz] [tofacitinib]




Cancer (leukemia)

  • Arzerra [ar-ZAYR-uh] [ofatumumab]

  • Asparlas [AS-par-las] [calaspargase pegol-mknl]

  • Besponsa [beh-SPON-suh] [inotuzumab ozogamicin]

  • Blincyto [blin-sye-toe] [blinatumomab]

  • Campath [KAM-path] [alemtuzumab]

  • Copiktra [koh-PIK-truh] [duvelisib]

  • Daurismo [DOOR-is-moh] [glasdegib]

  • Elspar [EL-spar] [asparaginase]

  • Erwinaze [ER-wih-nayz] [asparaginase erwinia chrysanthemi]

  • Gazyva [guh-ZY-vuh] [obinutuzumab)

  • Intron A [IN-tron-Aye] [interferon alfa-2b]

  • Kymriah [kim-rye-ah] [tisagenlecleucel]

  • Lumoxiti [loo-MOK-sih-tee] [moxetumomab pasudotox-tdfk]

  • Mylotarg [MY-loh-targ] [gemtuzumab ozogamicin]

  • Oncaspar [ON-kah-spar] [pegaspargase]

  • Riabni [re-AB-nee] [rituximab-arrx] (biosimilar)

  • Rituxan [rih-TUK-sun] [rituximab]

  • Rituxan Hycela [rih-TUK-sun hy-SEL-uh] [rituximab and hyaluronidase human]

  • Ruxience [RUKS-ee-ents] [rituximab-pvvr] (biosimilar)

  • Truxima [truk-SEE-muh] [rituximab-abbs] (biosimilar)

  • Venclexta [ven-KLEK-stuh] [venetoclax]

  • Xospata [zoh-SPAH-tuh] [gilteritinib]




Cancer (blood – including lymphoma and myeloma)

  • Adcetris [ad-SEH-tris] [brentuximab vedotin]

  • Blenrep [BLEN-rep] [belantamab mafodotin-blmf]

  • Darzalex [DAR-zah-lex] [daratumumab]

  • Darzalex Faspro [DAR-zah-lex Fass-pro] [daratumumab and hyaluronidase-fihj]

  • Empliciti [em-PLIH-sih-tee] [elotuzumab]

  • Epogen [EE-po-jen] [epoetin alfa]

  • Erwinaze [ER-wih-nayz] [asparaginase erwinia chrysanthemi]

  • Gazyva [guh-ZY-vuh] [obinutuzumab]

  • Keytruda [key-true-duh] [pembrolizumab]

  • Kymriah [kim-rye-ah] [tisagenlecleucel]

  • Monjuvi [mon-JOO-vee] [tafasitamab-cxix]

  • Ontak [ON-tak] [denileukin diftitox]

  • Polivy [poh-LIH-vee] [polatuzumab vedotin-piiq]

  • Procrit [PROH-crit] [epoetin alfa]

  • Retacrit [RET-a-crit] [epoetin alfa-epbx]

  • Riabni [re-AB-nee] [rituximab-arrx] (biosimilar)

  • Rituxan [rih-TUK-sun] [rituximab]

  • Rituxan Hycela [rih-TUK-sun hy-SEL-uh] [rituximab and hyaluronidase human]

  • Ruxience [RUKS-ee-ents] [rituximab-pvvr] (biosimilar)

  • Sarclisa [sar-KLIH-suh] [isatuximab-irfc]

  • Tecartus [tek-AR-tus] [brexucabtagene autoleucel]

  • Truxima [truk-SEE-muh] [rituximab-abbs] (biosimilar)

  • Zevalin [ZEH-vuh-lin] [ibritumomab tiuxetan]


Cancer (lung)

  • Avastin [uh-VAST-in] [bevacizumab]

  • Bavencio [buh-VEN-see-oh] [avelumab]

  • Cyramza [sy-RAM-zuh] [ramucirumab]

  • Epogen [EE-po-jen] [epoetin alfa]

  • Imfinzi [im-FIN-zee] [durvalumab]

  • Keytruda [key-true-duh][pembrolizumab]

  • Lorlatinib [lor-LA-ti-nib] [lorlatinib]

  • Mvasi [em-VAH-see] [bevacizumab-awwb] (biosimilar)

  • Opdivo [op-DEE-voh] [nivolumab]

  • Portrazza [por-TRA-zuh] [necitumumab]

  • Procrit [PROH-crit] [epoetin alfa]

  • Retacrit [RET-a-crit] [epoetin alfa-epbx]

  • Tecentriq [teh-SEN-trik] [atezolizumab]

  • Vizimpro [vih-ZIM-proh] [dacomitinib]

  • Zirabev (bevacizumab-bvzr) (biosimilar)




Cancer (skin—melanoma, squamous cell carcinoma, basal cell carcinoma)

  • Alferon N [al-FEER-on N] [interferon alfa-n3]

  • Braftovi [braf-TOH-vee] [encorafenib]

  • Keytruda [key-true-duh] [pembrolizumab]

  • Libtayo [lib-TY-oh] [cemiplimab-ydhp]

  • Opdivo [op-DEE-voh] [nivolumab]

  • Mektovi [mek-TOH-vee] [binimetinib]

  • Proleukin [proh-LOO-kin] [aldesleukin]

  • Yervoy [YER-voy] [ipilimumab]




Cancer (colorectal)

  • Avastin [uh-VAST-in] [bevacizumab]

  • Cyramza [sy-RAM-zuh] [ramucirumab]

  • Erbitux [ER-bih-tux] [cetuximab]

  • Mvasi [em-VAH-see] [bevacizumab-awwb] (biosimilar)

  • Vectibix [VEK-tih-bix] [panitumumab]

  • Yervoy [YER-voy] [ipilimumab]

  • Zaltrap [ZAL-trap] [ziv-aflibercept]

  • Zirabev [ZIE-rah-bev] [bevacizumab-bvzr] (biosimilar)




Cancer (breast)

  • Epogen [EE-po-jen] [epoetin alfa]

  • Herceptin [her-SEP-tin] [trastuzumab]

  • Herzuma [her-ZOO-muh] [trastuzumab-pkrb] (biosimilar)

  • Kadcyla [kad-SY-luh] [ado-trastuzumab emtansine]

  • Kanjinti [kan-jin-tee] [trastuzumab-anns] (biosimilar)

  • Margenza [MAR-jen-zuh] [margetuximab-cmkb]

  • Ogivri [oh-GIV-ree] [trastuzumab-dkst] (biosimilar)

  • Ontruzant [on-TRU-zant] [trastuzumab-dttb] (biosimilar)

  • Perjeta [per-JEH-tuh] [pertuzumab]

  • Phesgo [FES-goh] [pertuzumab, trastuzumab, and hyaluronidase-zzxf]

  • Procrit [PROH-crit] [epoetin alfa]

  • Retacrit [RET-a-crit] [epoetin alfa-epbx]

  • Talazoparib [TA-luh-ZOH-puh-rib] [talazaoparib]

  • Tecentriq [teh-SEN-trik] [atezolizumab]

  • Trazimera [tra-zee-MER-uh] [trastuzumab-qyyp] (biosimilar)

  • Trodelvy [troh-DEL-vee] [sacituzumab govitecan-hziy]




Cancer (kidney)

  • Avastin [uh-VAST-in] [bevacizumab]

  • Mvasi [em-VAH-see] [bevacizumab-awwb] (biosimilar)

  • Opdivo [op-DEE-voh] [nivolumab]

  • Proleukin [proh-LOO-kin] [aldesleukin]

  • Yervoy [YER-voy] [ipilimumab]

  • Zirabev (bevacizumab-bvzr) (biosimilar)




Cancer (other types)

  • Avastin [uh-VAST-in] [bevacizumab]

  • Cyramza [sy-RAM-zuh] [ramucirumab]

  • Danyelza [dan-YEL-zah] [naxitamab-gqg]

  • Elzonris [el-ZON-ris] [tagraxofusp-erz]

  • Epogen [EE-po-jen] [epoetin alfa]

  • Erbitux [ER-bih-tux] [cetuximab]

  • Keytruda [key-true-duh] [pembrolizumab]

  • Lartruvo [lar-TROO-voh] [olaratumab]

  • Lenvima [len-VEE-muh] [lenvatinib]

  • Lynparza [lin-PAR-zuh] [olaparib]

  • Mvasi [em-VAH-see] [bevacizumab-awwb] (biosimilar)

  • Poteligeo [poh-teh-LIH-gee-oh] [mogamuliziumab]

  • Procrit [PROH-crit] [epoetin alfa]

  • Retacrit [RET-a-crit] [epoetin alfa-epbx]

  • Tecentriq [teh-SEN-trik][atezolizumab]

  • Zirabev (bevacizumab-bvzr) (biosimilar)


Neutropenia (from cancer treatment)

  • Fulphila [FUL-fih-luh] [pegfilgrastim-jmdb] (biosimilar)

  • Granix [GRA-nix] [tbo-filgrastim]

  • Neulasta [noo-LA-stuh] [pegfilgrastim]

  • Neupogen [NOO-poh-jen] [filgrastim]

  • Nivestym [NAI-vuh-stim] [filgrastim-aafi] (biosimilar)

  • Nyvepria [NAI-vee-pri-ah] [pegfilgrastim-apgf] (biosimilar)

  • Udenyca [yoo-den-i-kah] [pegfilgrastim-cbqv] (biosimilar)

  • Zarxio [ZAR-zee-oh] [filgrastim-sndz] (biosimilar)

  • Ziextenzo [zee-ex-TEN-zo] [pegfilgrastim-bmez] (biosimilar)




Crohn's Disease

  • Avsola [av-SO-luh] [infliximab-axxq] (biosimilar)

  • Cimzia [SIM-zi-ah] [certolizumab]

  • Entyvio [en-TIV-ee-oh] [vedolizumab]

  • Humira [hu-MEER-ah] [adalimumab]

  • Inflectra [In-flec-tra] [infliximab-dyyb] (biosimilar)

  • Ixifi [ix-IF-ee] [infliximab-qbtx] (biosimilar)

  • Remicade [REM-i-cade] [infliximab]

  • Renflexis [ren-FLEX-is] [infliximab-abda] (biosimilar)

  • Stelara [ustekinumab]

  • Tysabri [tai-SAB-ree] [natalizumab]




Ulcerative Colitis

  • Avsola [av-SO-luh] [infliximab-axxq] (biosimilar)

  • Entyvio [en-TIV-ee-oh] [vedolizumab]

  • Humira [hu-MEER-ah] [adalimumab]

  • Inflectra [In-flec-tra] [infliximab-dyyb] (biosimilar)

  • Ixifi [ix-IF-ee] [Infliximab-qbtx] (biosimilar)

  • Remicade [REM-i-cade] [infliximab]

  • Renflexis [ren-FLEX-is] [infliximab-abda] (biosimilar)

  • Simponi [SIM-poh-nee] [golimumab]

  • Stelara [stuh-LAIR-ah] [ustekinumab]

  • Xeljanz [ZEL-janz] [tofacitinib]




Eczema/Atopic Dermatitis

  • Dupixent [due-PIX-ent] [dupilumab]


Psoriasis

  • Avsola [av-SO-luh] [infliximab-axxq] (biosimilar)

  • Cimzia [SIM-zi-ah] [certolizumab]

  • Cosentyx [koh-SEN-tix] [secukinumab]

  • Enbrel [EN-brel] [etanercept]

  • Erelzi [Ee-REL-zee] [etanercept-szzs] (biosimilar)

  • Eticovo [Et-uh-co-vo] [etanercept-ykro] (biosimilar)

  • Humira [hu-MEER-ah] [adalimumab]

  • Ilumya [e-loom-e-a] [tildrakizumab]

  • Inflectra [In-flec-tra] [infliximab-dyyb] (biosimilar)

  • Ixifi [ix-IF-ee] [infliximab-qbtx] (biosimilar)

  • Otezla [oh-TEZ-la] [apremilast]

  • Remicade [REM-i-cade] [infliximab]

  • Renflexis [ren-FLEX-is] [infliximab-abda] (biosimilar)

  • Siliq [sill-EEK] [brodalumb]

  • Skyrizi [sky-RI-zee] [risankizumab]

  • Stelara [stuh-LAIR-ah] [ustekinumab]

  • Taltz [taltz] [lxekizumab]

  • Tremfya [trem-FAI-ah] [guselkumab]

  1. Please fill in the following information about each medicine that you selected.

[Populate first two columns based on Q19 responses]

[If currently taking any medicine for more than one month, proceed to Q21]

[If not currently taking a medicine, but the medicine was taken within the last year and taken for more than one month, proceed to Q21]



Medicine

Condition

Are you still taking this medicine?

YES

How long have you been taking it?

NO

When did you last take this medicine?

How long did you take this medicine when you were still using it?

[Medicine]

[Condition]

  • Yes

  • No

  • Less than one month

  • 1-3 months

  • 4-6 months

  • 7-12 months

  • More than one year

  • Within the last month

  • 1-3 months ago

  • 4-6 months ago

  • More than 6 months ago

  • Less than one month

  • More than one month

[Medicine]

[Condition]

  • Yes

  • No

  • Less than one month

  • 1-3 months

  • 4-6 months

  • 7-12 months

  • More than one year

  • Within the last month

  • 1-3 months ago

  • 4-6 months ago

  • More than 6 months ago

  • Less than one month

  • More than one month

[Medicine]

[Condition]

  • Yes

  • No

  • Less than one month

  • 1-3 months

  • 4-6 months

  • 7-12 months

  • More than one year

  • Within the last month

  • 1-3 months ago

  • 4-6 months ago

  • More than 6 months ago

  • Less than one month

  • More than one month

  1. Would you be comfortable discussing this medicine/these medicines in an interview?

Yes

ELIGIBLE

No

TERMINATE







Demographic Questions

  1. What is the highest level of education you have completed?

  • Less than high school diploma [Eligible for lower education groups]

  • High school graduate or GED [Eligible for lower education groups]

  • Some college

  • Technical or associates degree (2-year)

  • 4-year degree

  • Graduate or professional degree [RECRUIT NO MORE THAN 14% OF SAMPLE]

  1. What type of health insurance do you currently have? [Accept multiple responses]

  • Private insurance through an employer, group health plan, broker, agent, or Federal or state marketplace plan

  • Medicaid or Medicare [RECRUIT 30% OF TOTAL SAMPLE NON-PRIVATE]

  • Veterans Affairs, Tricare, or the Department of Defense [RECRUIT 30% OF TOTAL SAMPLE NON-PRIVATE]

  • Currently uninsured

  • Other [please specify]: _______________________

  1. What is your race? You may select more than one. [Accept multiple responses]

  • White [RECRUIT NO MORE THAN 80% OF SAMPLE]

  • Black or African American

  • Asian

  • Native Hawaiian or Other Pacific Islander

  • American Indian or Alaska Native

  1. Are you of Hispanic, Latino, or Spanish origin?

  • Yes [RECRUIT 15% OF SAMPLE]

  • No

  1. In which state do you live? [Display drop down list. Recruit at least 20% in each Census region.]

[drop down list of states]

  1. What was your total household income before taxes during the past 12 months? Your response will be kept private.

  • $30,000 or less [RECRUIT MINIMUM 20% OF SAMPLE < $30,000]

  • $30,001 to $65,000

  • $65,001 to $99,999

  • More than $100,000

  • Prefer not to answer

  1. What is your sex?

  • Male [RECRUIT AT LEAST 40% OF SAMPLE]

  • Female [RECRUIT AT LEAST 40% OF SAMPLE]



Closing Scripts

Declined to Begin Screener

Thank you for your time.

Completed Screener

You have completed the online screener. One of our recruiters will be in touch if you qualify for this study. Thank you for your time.

9


File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
AuthorAlexander, Jennifer
File Modified0000-00-00
File Created2022-07-11

© 2024 OMB.report | Privacy Policy